# Glanbia account plan

> Glanbia is an Irish nutrition group behind Optimum Nutrition and B2B nutrition ingredients, with FY2025 revenue of $3,946.4m and 5,800 employees.

## At a glance

Glanbia plc is an Irish nutrition group that sells sports and lifestyle nutrition brands (Optimum Nutrition, Isopure, think!) and B2B nutrition ingredients such as custom premixes, flavours, whey protein solutions and bioactives, plus American-style cheddar cheese in the US. Its brands and ingredients are sold in 120+ markets, from 27 manufacturing sites and 20 innovation and collaboration centres, and the US is its largest market with $2,660.5m of FY2025 revenue. In FY 2025 (52 weeks to 3 January 2026) revenue was $3,946.4m, pre-exceptional EBITDA $499.1m and profit after tax $183.3m, with 5,800 employees. Glanbia is listed, and Tirlán Co-op is its largest shareholder, with 13.18% after a directed buyback in June 2026.

## Business units

- **Performance Nutrition** (about 46% of FY2025 revenue ($1,801.1m)): Sports and lifestyle nutrition brands sold to consumers online, in food, drug, mass and club retail, specialty stores and through distributors. Optimum Nutrition made 79% of segment revenue in 2026 and grew like-for-like by 25.8% in the first nine months of 2026, driven by pricing in response to whey inflation. Led by Monica McGurk (Americas) and Andy Shaw (International).
- **Health & Nutrition** (about 16% of FY2025 revenue ($628.5m)): B2B partner delivering custom premix solutions, value-added ingredients and clean-label flavour systems to brands in active nutrition, functional beverages and vitamins, minerals and supplements. Revenue grew 11.5% at constant currency in FY2025 with an 18.4% EBITDA margin, helped by the Sweetmix and Scicore acquisitions. Led by Arnaud Schuh.
- **Dairy Nutrition** (about 38% of FY2025 revenue ($1,516.8m)): Whey protein solutions, bioactive ingredients such as colostrum, and American-style cheddar cheese marketed with the MWC-Southwest joint venture to US retail and food service; cheese is about two-thirds of segment revenue. FY2025 EBITDA was $149.5m, and FY 2026 EBITDA is guided at $175-180m. Led by Tom Tench.

## Strategic priorities

- **Capital Markets Day targets 2026-2028**: Adjusted EPS growth of 7-11% a year at constant currency, OCF conversion of 85%+, ROCE of 10-13% and a 30-40% dividend payout; organic revenue growth of 5-7% a year in Performance Nutrition and 4-6% in Health & Nutrition, and Dairy Nutrition EBITDA of $150-160m a year.
- **Grow Optimum Nutrition globally**: Driving Optimum Nutrition is the first of five strategic priorities, backed by the global Optimum Advantage campaign and a double-digit dollar increase in marketing for the brand in 2026 and 2027.
- **Scale Health & Nutrition**: Scale H&N as a solutions partner through mid-market customer acquisition, cross-selling, targeted acquisitions and capacity expansion in the US, China and Europe expected by early 2027.
- **Transformation savings**: The group-wide transformation programme now targets $70m a year of savings by FY 2027 (raised from $60m), through supply chain centres of excellence, outsourced back-office functions, new Finance and HR systems and AI-enabled tools.
- **International expansion**: Expand internationally and leverage global scale, including a 5% inventory reduction over three years; PN International grew like-for-like by 28.3% in the first nine months of 2026.

## Latest results

In the nine months to 3 October 2026, group like-for-like revenue grew 9.9% (volume +4.2%, price +5.7%) to $3.2bn, and Performance Nutrition grew 18.0% like-for-like on pricing taken against whey inflation. In H1 2026 (six months to 4 July 2026), revenue was $2,079.4m, up 7.0% at constant currency, pre-exceptional EBITDA rose 14.1% to $275.4m and adjusted EPS rose 30.0% at constant currency. FY 2026 guidance was raised twice and now calls for adjusted EPS growth of 22-24% at constant currency, PN like-for-like growth of 16-17% and Dairy Nutrition EBITDA of $175-180m. Net debt was $704m at 3 October 2026.

## Investments and deals

- **Health & Nutrition acquisitions**: Sweetmix (Brazil premix) acquired in 2025 for initial consideration of $41.4m, and Scicore (India) completed in January 2026 for about $16.4m; management describes the M&A pipeline as very active, primarily in H&N.
- **Capacity expansion**: A second building at the Suzhou, China premix plant to more than double capacity, a flavour spray-drying centre and a collaboration centre in Sharonville, and WPI capacity at the MWC-Southwest joint venture from early 2027; FY 2026 capex is guided at $100-110m.
- **Portfolio divestments**: SlimFast and Body & Fit were divested in 2025, with a $45.7m loss on disposal.
- **Shareholder returns**: €197.2m of buybacks in 2025 and a further €100m in 2026, half of it a directed buyback from Tirlán.

## Challenges and risks

- **Whey input cost inflation**: Record whey protein costs cut the Performance Nutrition EBITDA margin by 380bps to 13.0% in FY2025; whey for 2027 is procured at higher cost, so further price increases are expected in H1 2027.
- **Price elasticity**: After three price increases in 12 months, PN volumes fell 4.7% in Q3 2026 on tough US comparatives, with elasticity concentrated in specific channels and pack sizes.
- **Tariffs and geopolitics**: Geopolitical, economic, market disruption and cybersecurity risks are rated elevated; Middle East-related raw material costs weighed on the H&N margin, which fell 110bps in H1 2026.
- **Weaker brands in the portfolio**: Isopure lost a club-channel listing and other portfolio brands declined in PN Americas; think! is due for a relaunch in Q2 2027.
- **Cybersecurity during digital transformation**: The annual report flags new vulnerabilities from AI and emerging technologies and the need for controls during the digital transformation.

## What leadership says

> "We are reshaping Glanbia into a more focused, higher-growth nutrition business." — Hugh McGuire, Chief Executive Officer, Annual Report and Financial Statements 2025, March 2026

> "fundamentally, whey price drop is good for the group. We are a far bigger buyer of high-end whey proteins than we are a manufacturer" — Hugh McGuire, Chief Executive Officer, Q3 2026 interim management statement call, 4 November 2026

> "Our task now is to accelerate the execution of our Capital Markets Day strategy, to ensure we deliver on a consistent basis over the coming years." — Paul Duffy, Group Chair, Annual Report and Financial Statements 2025, March 2026

> "We delivered volume and like-for-like revenue growth across all three segments, reflecting disciplined execution as we continue to navigate whey cost inflation within Performance Nutrition." — Hugh McGuire, Chief Executive Officer, Half Year 2026 Results, 6 August 2026


## Where a supplier can help

- **Protein ingredient supply and hedging**: Tied to whey input cost inflation: alternative protein sources, procurement analytics or risk tools that reduce exposure to whey price swings.
- **Automation and AI in shared services**: Tied to the transformation programme and its $70m savings target: back-office outsourcing, process automation, Finance and HR systems and AI-enabled tools.
- **Equipment and construction for new capacity**: Tied to the capacity expansion in the US, China and Europe and $100-110m of FY 2026 capex: blending, spray-drying, packaging and plant engineering suppliers.
- **Pricing and revenue management**: Tied to price elasticity: pack-size, promotion and channel analytics that help sustain volume after repeated price increases.
- **Security for a changing IT estate**: Tied to the elevated cybersecurity risk during digital transformation: security services covering new systems and AI deployments.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report and Financial Statements 2025](https://www.glanbia.com/sites/glanbia-plc/files/glanbia/investors/annual-report/2026/Glanbia-Annual-Report-2025.pdf)

Annual report · 2026-03-11

- Glanbia plc is an Irish "Better Nutrition" group selling sports and lifestyle nutrition brands (Optimum Nutrition, Isopure, think!) and B2B nutrition ingredients (premixes, flavours, whey protein solutions, bioactives) plus US American-style cheddar cheese; 5,800 employees, 27 manufacturing sites and 20 innovation and collaboration centres (including joint venture), brands and ingredients sold in 120+ markets.
- FY 2025 (52 weeks to 3 January 2026): revenue $3,946.4m (+2.3% constant currency, +2.8% reported), pre-exceptional EBITDA $499.1m (-9.4% constant currency), adjusted EPS 134.93 $c (-3.4% constant currency), profit after tax $183.3m; "unprecedented whey input cost inflation", tariffs and macro volatility hit Performance Nutrition.
- Three segments since January 2025: Performance Nutrition (PN, revenue $1,801.1m, EBITDA margin 13.0%), Health & Nutrition (H&N, $628.5m, margin 18.4%) and Dairy Nutrition (DN, $1,516.8m, margin 9.9%); Optimum Nutrition alone achieved revenue of over $1.3bn and LFL growth of 6.4%.
- The US is the main market: $2,660.5m of revenue by place of delivery, followed by Europe excluding Ireland ($537.9m) and Asia Pacific ($431.2m).
- Capital Markets Day (November 2025) targets for 2026-2028: adjusted EPS growth 7-11% a year (constant currency), OCF conversion 85%+, ROCE 10-13%, dividend payout 30-40%; PN organic revenue growth 5-7% a year, H&N 4-6%, DN EBITDA $150-160m a year.
- Five strategic priorities: drive Optimum Nutrition and grow PN globally with lifestyle brands, scale H&N as a solutions partner, optimise DN to maximise profits, expand internationally, innovate.
- Group-wide transformation programme now on track for $60m+ of annual savings by 2027 (initial target $50m), with expected costs of $100m; it separated Glanbia Nutritionals into H&N and DN, centralises supply chain functions into centres of excellence, outsources back-office functions and uses AI-enabled tools.
- Portfolio moves: SlimFast and Body & Fit divested in 2025; Sweetmix (Brazil premix, $41.4m initial consideration) acquired; Scicore (India, about $16.4m) completed in January 2026; WPI capacity expansion committed at the MWC-Southwest joint venture; premix capacity in Suzhou, China to more than double.
- Strong cash: OCF $454.4m (91.0% conversion), free cash flow $359.8m, net debt $526.0m (1.08x EBITDA); €197.2m of buybacks in 2025, total dividend 42.87 €cent (+10%), a further €100m buyback authorised for 2026.
- Leadership: Hugh McGuire CEO, Mark Garvey CFO, Paul Duffy Group Chair from 1 January 2026; Tirlán Co-op holds 17.86% and remains the largest shareholder. Elevated risks: geopolitics, economic and industry conditions, market disruption, cybersecurity and data protection.

### [Half Year 2026 Results (six months ended 4 July 2026)](https://www.glanbia.com/sites/glanbia-plc/files/glanbia/investors/results-presentations/2026/Glanbia-HY26-Results.pdf)

Interim report · 2026-08-06

- H1 2026 (six months to 4 July 2026): revenue $2,079.4m (+7.0% constant currency, +7.9% reported), pre-exceptional EBITDA $275.4m (+14.1%), margin 13.2% (+80bps constant currency), adjusted EPS 81.24 $cent (+30.0% constant currency), ahead of expectations.
- LFL revenue growth of 10.7% (volume +8.2%, price +2.5%), partly offset by a 3.7% drag from net acquisitions/disposals (non-core brands sold in 2025).
- Performance Nutrition: LFL +16.9% (volume +9.3%, price +7.6%); Optimum Nutrition (79% of PN revenue) LFL +25.2%; EBITDA $115.2m, margin 12.6%, as pricing, transformation savings and disposals largely offset whey inflation.
- Health & Nutrition: LFL +12.0% with volume +14.3%; revenue $368.5m; margin 18.4% (-110bps on raw material costs); capacity expansion in the US, China and Europe on schedule.
- Dairy Nutrition: EBITDA $92.3m (+28.2%), margin 11.6%, on double-digit volume and pricing growth in protein solutions; joint venture profit share $12.7m.
- FY 2026 guidance upgraded: adjusted EPS growth 17-20% constant currency (previously upper end of 7-11%), PN LFL 12-14%, H&N LFL 8-10%, DN EBITDA $170-180m; capex $100-110m.
- Transformation savings target raised from $60m to $70m a year by FY 2027.
- Net debt $730.5m (1.41x EBITDA); interim dividend +10% to 18.92 €cent; €100m returned via buybacks, including a €50m directed buyback from Tirlán, whose stake fell to 13.18%; Tirlán's Board representation cut from two to one director.

### [Third Quarter 2026 Interim Management Statement](https://www.glanbia.com/sites/glanbia-plc/files/glanbia/investors/results-presentations/2026/Glanbia-Q3-IMS-2026.pdf)

Interim report · 2026-11-04

- Q3 2026 interim management statement (nine months to 3 October 2026, published 4 November 2026): group LFL revenue +9.9% (volume +4.2%, price +5.7%), total constant-currency revenue +6.7% after a 3.2% drag from net disposals.
- Performance Nutrition LFL +18.0% (volume +4.3%, price +13.7%); Optimum Nutrition (79% of PN revenue) LFL +25.8%, Q3 LFL +26.9% (+0.8% volume, +26.1% price); US consumption +22.9% in the last 13 weeks.
- PN Americas (60% of PN revenue) LFL +11.8%; PN International (40%) LFL +28.3%; other portfolio brands declined.
- Health & Nutrition LFL +9.8% with volume +11.5%; total +12.8% including Sweetmix and Scicore; pricing -1.7% from tariff refunds and volume rebates.
- Dairy Nutrition LFL +2.1%: double-digit pricing in protein solutions, offset by negative cheese pricing.
- FY 2026 guidance raised again: adjusted EPS growth 22-24% constant currency (previously 17-20%), PN LFL 16-17% (previously 12-14%), DN EBITDA $175-180m.
- Net debt $704m with $1.3bn of committed facilities; Wendy Chang Smith appointed CFO Designate, becoming CFO and Executive Director from 31 March 2027.

### [Glanbia H1 2026 results call (transcript)](https://stockanalysis.com/quote/ise/GL9/transcripts/554261-h1-2026/)

Executive talk · Hugh McGuire, Chief Executive Officer · 2026-08-06

- Hugh McGuire (CEO) and Mark Garvey (CFO) present H1 2026: adjusted EPS +30% constant currency, EBITDA $275.4m (+14.1%), margin 13.2%; FY 2026 adjusted EPS guidance raised to 17-20% growth.
- Transformation savings target raised to $70m a year by 2027 (about 40% delivered by end 2026, at least 50% reinvested in growth); total programme charges now about $110m, about $85m incurred.
- Performance Nutrition took double-digit price increases in Q2 and more in Q3; only "limited elasticity" so far, and Optimum Nutrition showed the highest resilience to pricing among brands tested in a US survey.
- Whey: needs procured for 2026 and to early Q2 2027; 2027 costs higher than 2026, so further price increases expected late 2026 or early 2027; own WPI capacity in the joint venture from early 2027.
- McGuire sees a structural shift: new whey supply "has been taken up by demand"; GLP-1 and the inverted US food pyramid are tailwinds; Glanbia is the biggest buyer of whey protein ingredients globally, with a natural hedge through Dairy Nutrition.
- H&N: LFL +12% partly from customer pipeline fill; margins hit by Middle East-related raw material costs, still guided at 17-19%; new collaboration centre in Montreal; capacity in the US, Europe and China by early 2027.
- Cheese is about two-thirds of Dairy Nutrition revenue; DN EBITDA guided at $170-180m; joint venture profit about $20m.
- M&A pipeline "very active", primarily in Health & Nutrition; net debt/EBITDA expected around 1x at year end.

### [Glanbia Q3 2026 interim management statement call (transcript)](https://stockanalysis.com/quote/ise/GL9/transcripts/729051-q3-2026/)

Executive talk · Hugh McGuire, Chief Executive Officer · 2026-11-04

- On the Q3 2026 call (4 November 2026), Hugh McGuire (CEO) and Mark Garvey (CFO) raised FY 2026 adjusted EPS growth guidance to 22-24% constant currency; nine-month LFL revenue +9.9% to $3.2bn.
- Optimum Nutrition volume grew 0.8% in Q3 despite pricing above 20%, after three price increases in 12 months; PN volumes fell 4.7% in Q3 on tough US comparatives.
- High-end whey prices softened on one variant (WPC80) after an 80-100% spike over two quarters; whey for H1 2027 is substantially procured at higher cost, so price increases are likely in H1 2027, with none before year end.
- Garvey: a whey price fall "is good for the group", because Glanbia buys far more high-end whey than it makes; DN is more insulated because most of its protein business is now solutions.
- Marketing about 6% of revenue in 2026, with a double-digit dollar increase for Optimum Nutrition and a similar rise planned for 2027; think! relaunch in Q2 2027, Isopure back in growth in North America from early 2027.
- Medium term: PN revenue growth in 2027 likely at or above the 5-7% range from pricing alone; the 250bps PN margin goal by 2028 is maintained, helped by $70m of transformation savings in full in 2027.
- M&A pipeline active, focused on scaling Health & Nutrition, but some valuations are "a little bit frothy"; Wendy Chang Smith named CFO Designate to succeed Garvey.

## Questions about Glanbia

### What does Glanbia do?

Glanbia sells sports and lifestyle nutrition brands led by Optimum Nutrition, supplies custom premixes, flavours and whey protein solutions to other brands, and markets American-style cheddar cheese in the US.

### What is Glanbia's revenue?

FY 2025 revenue was $3,946.4m with pre-exceptional EBITDA of $499.1m. In H1 2026 revenue was $2,079.4m, up 7.0% at constant currency.

### How many employees does Glanbia have?

Glanbia counts 5,800 employees, 27 manufacturing sites and 20 innovation and collaboration centres, including the joint venture.

### What is Glanbia's strategy?

Five priorities: drive Optimum Nutrition, scale Health & Nutrition as a solutions partner, optimise Dairy Nutrition, expand internationally and innovate, supported by a transformation programme targeting $70m of annual savings by FY 2027.

### Who leads Glanbia?

Hugh McGuire is CEO and Mark Garvey CFO; Wendy Chang Smith becomes CFO from 31 March 2027. Paul Duffy has been Group Chair since 1 January 2026.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
